Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript

Thank you for standing by, and welcome to the Corcept Therapeutics Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Atabak Mokari, CFO. Please go ahead, sir. Atabak Mokari CFO & Treasurer Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors, Past Events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available on the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our revenue in the second quarter of 2026 was $256.1 million, a 32% increase over the prior-year period. Korlym and authorized generic product revenue was $208.6 million. Lifyorli